Researchers are excited about the medication , a novel dual agonist showing promising outcomes in early trials for body loss . It functions by modulating two pathways : GLP-1 and GIP, which , when https://kallumywme285934.blogkoo.com/a-new-possibility-for-body-reduction-60390874